Safety and efficacy of BAY 94–9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Elena Santagostino, Shadan Lalezari, Mark T. Reding, Jonathan Ducore, Heng Joo Ng, Lone H. Poulsen, Lisa A. Michaels, Camila Linardi

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
JournalHaemophilia
DOIs
StateAccepted/In press - 2021

Bibliographical note

Funding Information:
Medical writing assistance was provided by Graeme Baldwin and Frank Biegun of Darwin Healthcare Communications, funded by Bayer.

Funding Information:
Elena Santagostino has participated in speaker bureaux and advisory boards from Bayer, Shire/Takeda, CSL Behring, Novo Nordisk, Roche, Grifols, Kedrion, Octapharma, Pfizer, UniQure, Spark, Sobi and Bioverativ. Shadan Lalezari has participated in advisory boards for Bayer and received honoraria or consultation fees from Bayer, Teva Pharmaceuticals, Takeda, PI Healthcare, Roche and Pfizer. Mark T. Reding has received institutional research support from Bayer and BioMarin and has participated in advisory boards and speaker bureaux for Bayer, Novo Nordisk, Sanofi Genzyme and Takeda. Jonathan Ducore has received honoraria or consultation fees from Octapharma, Bayer, Shire and HEMA Biologics; and speaking or presenting fees from Bayer and HEMA Biologics. Heng Joo Ng has nothing to disclose. Lone H. Poulsen has received grants and research support from Pfizer and has supported Bayer, Novo Nordisk, Sobi, Pfizer and Octapharma with congresses. Lisa A. Michaels was an employee of Bayer at the time of manuscript submission. Camila Linardi is an employee of Bayer.

Keywords

  • clinical outcome
  • clinical trials
  • extended half-life
  • factor VIII
  • haemophilia A
  • minor surgery
  • PEGylation

PubMed: MeSH publication types

  • Letter

Cite this